Antiviral_JJ Activity_NN of_IN Limitin_NP against_IN Encephalomyocarditis_NP Virus_NP ,_, Herpes_NP Simplex_NP Virus_NP ,_, and_CC Mouse_NP Hepatitis_NP Virus_NP :_: Diverse_JJ Requirements_NNS by_IN Limitin_NP and_CC Alpha_NP Interferon_NP for_IN Interferon_NP Regulatory_NP Factor_NP 1_CD Limitin_NP has_VBZ sequence_NN homology_NN with_IN alpha_NN interferon_NN (_( IFN-alpha_NP )_) and_CC IFN-beta_NP and_CC utilizes_VBZ the_DT IFN-alpha/beta_NP receptor_NN ._SENT However_RB ,_, it_PP has_VBZ no_DT influence_NN on_IN the_DT proliferation_NN of_IN normal_JJ myeloid_JJ and_CC erythroid_JJ progenitors_NNS ._SENT In_IN this_DT study_NN ,_, we_PP show_VBP that_IN limitin_NN has_VBZ antiviral_JJ activity_NN in_IN vitro_NN as_IN well_RB as_RB in_IN vivo_RB ._SENT Limitin_NP inhibited_VBD not_RB only_RB cytopathic_JJ effects_NNS in_IN encephalomyocarditis_NN virus-_NN or_CC herpes_NN simplex_NN virus_NN (_( HSV_NP )_) type_NN 1-infected_JJ L929_NP cells_NNS ,_, but_CC also_RB plaque_NN formation_NN in_IN mouse_NN hepatitis_NN virus_NN (_( MHV_NP )_) type_NN 2-infected_JJ DBT_NN cells_NNS ._SENT In_IN addition_NN ,_, administration_NN of_IN limitin_NN to_TO mice_NNS suppressed_VBN MHV-induced_NP hepatitis_NP and_CC HSV-induced_NP death_NN ._SENT The_DT antiviral_JJ activity_NN may_MD be_VB mediated_VBN in_IN part_NN by_IN 2',5'-oligoadenylate_JJ synthetase_NN ,_, RNA-dependent_NP protein_NN kinase_NN ,_, and_CC Mx_NP protein_NN ,_, which_WDT inhibit_VBP viral_JJ replication_NN or_CC degrade_VB viral_JJ components_NNS ,_, because_IN limitin_NN induced_VBD their_PP$ mRNA_NN expression_NN and_CC enzyme_NN activity_NN ._SENT While_IN limitin_NN has_VBZ antiviral_JJ activity_NN as_IN strong_JJ as_RB that_IN of_IN IFN-alpha_NP in_IN vitro_NP (_( the_DT concentration_NN that_WDT provided_VBD 50_CD %_NN inhibition_NN of_IN cytopathic_JJ effect_NN is_VBZ similar30_JJ pg/ml_NN )_) ,_, IFN_NP regulatory_JJ factor_NN 1_CD (_( IRF-1_NP )_) dependencies_NNS for_IN induction_NN of_IN an_DT antiviral_JJ state_NN were_VBD different_JJ for_IN limitin_NP and_CC IFN-alpha_NP ._SENT In_IN IRF-1-deficient_JJ fibroblasts_NNS ,_, a_DT higher_JJR concentration_NN of_IN limitin_NN than_IN of_IN IFN-alpha_NP was_VBD required_VBN for_IN the_DT induction_NN of_IN antiviral_JJ activity_NN and_CC the_DT transcription_NN of_IN proteins_NNS from_IN IFN-stimulated_JJ response_NN element_NN ._SENT The_DT unique_JJ signals_NNS and_CC the_DT fewer_JJR properties_NNS of_IN myelosuppression_NN suggest_VBP that_IN a_DT human_JJ homolog_NN of_IN limitin_NN may_MD be_VB used_VBN as_IN a_DT new_JJ antiviral_JJ drug_NN ._SENT Interferons_NNS (_( IFNs_NP )_) are_VBP divided_VBN into_IN two_CD major_JJ groups_NNS of_IN biologically_RB active_JJ proteins_NNS ._SENT IFN-alpha_NP ,_, IFN-beta_NP ,_, IFN-omega_NP ,_, and_CC IFN-tau_NP ,_, which_WDT belong_VBP to_TO the_DT IFN-alpha/beta_NP family_NN ,_, have_VBP structural_JJ homology_NN to_TO each_DT other_JJ and_CC share_VB a_DT common_JJ receptor_NN ._SENT IFN-gamma_NP is_VBZ a_DT product_NN of_IN activated_VBN T_NN lymphocytes_NNS and_CC natural_JJ killer_NN cells_NNS ._SENT Although_IN only_JJ small_JJ amounts_NNS of_IN IFNs_NNS are_VBP produced_VBN under_IN steady-state_NN conditions_NNS ,_, these_DT can_MD be_VB markedly_RB increased_VBN by_IN virus_NN infections_NNS or_CC by_IN exposure_NN to_TO double-stranded_JJ nucleic_JJ acids_NNS ._SENT IFNs_NNS are_VBP highly_RB pleiotropic_JJ cytokines_NNS with_IN potent_JJ immunoregulatory_NN and_CC antiproliferative_JJ properties_NNS in_IN addition_NN to_TO their_PP$ antiviral_JJ activities_NNS ._SENT IFNs_NNS regulate_VBP immune_JJ responses_NNS ,_, such_JJ as_IN major_JJ histocompatibility_NN antigen_NN expression_NN ,_, cytokine_NN production_NN ,_, and_CC T-lymphocyte_NN activation_NN ._SENT IFNs_NNS suppress_VBP the_DT proliferation_NN of_IN many_JJ normal_JJ and_CC transformed_VBN cells_NNS through_IN prolongation_NN of_IN the_DT G1_JJ phase_NN of_IN the_DT cell_NN cycle_NN and_CC reduce_VB the_DT rate_NN of_IN entry_NN into_IN the_DT S_NP phase_NN ,_, as_RB well_RB as_IN inducing_VBG apoptosis_NN ._SENT The_DT antiviral_JJ activity_NN of_IN IFNs_NP results_NNS in_IN part_NN from_IN induction_NN of_IN the_DT enzymes_NNS 2',5'-oligoadenylate_JJ synthetase_NN (_( 2',5'-OAS_JJ )_) and_CC RNA-dependent_NP protein_NN kinase_NN (_( PKR_NP )_) and_CC of_IN Mx_NP protein_NN ,_, which_WDT inhibit_VBP viral_JJ replication_NN or_CC degrade_VB viral_JJ components_NNS ._SENT These_DT broad_JJ biological_JJ properties_NNS have_VBP suggested_VBN many_JJ clinical_JJ applications_NNS in_IN cancer_NN and_CC virologic_JJ diseases_NNS ._SENT Limitin_NP is_VBZ an_DT IFN-like_JJ cytokine_NN that_IN we_PP recently_RB cloned_VBD on_IN the_DT basis_NN of_IN its_PP$ ability_NN to_TO arrest_VB the_DT growth_NN of_IN or_CC kill_VB a_DT myelomonocytic_JJ leukemia_NN cell_NN line_NN ._SENT The_DT initial_JJ cDNA_NN clone_NN carried_VBD a_DT 997-bp_NN insert_NN (_( EMBL-GenBank-DDBJ_NP accession_NN number_NN )_) whose_WP$ deduced_VBN protein_NN is_VBZ composed_VBN of_IN 182_CD amino_NN acid_NN residues_NNS ._SENT It_PP contains_VBZ a_DT signal_NN peptide_NN of_IN 21_CD amino_NN acids_NNS at_IN the_DT N-terminal_JJ end_NN and_CC one_CD N-linked_JJ glycosylation_NN site_NN at_IN amino_NN acid_NN residue_NN 68_CD but_CC lacks_VBZ an_DT internal_JJ transmembrane_NN domain_NN ._SENT In_IN addition_NN ,_, limitin_NN protein_NN was_VBD detected_VBN in_IN the_DT supernatants_NNS of_IN transfectants_NNS with_IN an_DT expression_NN plasmid_NN of_IN limitin_NN ._SENT Thus_RB ,_, limitin_NN seems_VBZ to_TO be_VB a_DT secreted_VBN glycoprotein_NN ._SENT Analysis_NN with_IN the_DT translated_VBN protein_NN sequence_NN reveals_VBZ that_IN limitin_NN has_VBZ similar30_JJ %_NN identity_NN with_IN IFN-alpha_NP ,_, IFN-beta_NP ,_, and_CC IFN-omega_NP ._SENT Computer_NN modeling_NN of_IN limitin_NN structure_NN shows_VBZ an_DT IFN-like_JJ globular_JJ structure_NN composed_VBN of_IN five_CD long_JJ alpha-helices_NNS and_CC one_CD short_JJ helix_NN in_IN the_DT middle_NN of_IN the_DT loop_NN connecting_VBG helices_NNS B_NP and_CC C_NP ,_, with_IN possible_JJ disulfide_NN bonds_NNS between_IN residues_NNS 52_CD and_CC 157_CD and_CC between_IN residues_NNS 80_CD and_CC 130_CD ._SENT In_IN addition_NN ,_, receptor-binding_NN assays_NNS and_CC experiments_NNS using_VBG IFN-alpha/beta_NP receptor-deficient_NN cells_NNS have_VBP indicated_VBN that_IN limitin_NN binds_NNS to_TO and_CC utilizes_VBZ the_DT IFN-alpha/betareceptor_NN ._SENT Thus_RB ,_, limitin_NN seems_VBZ to_TO be_VB a_DT new_JJ member_NN of_IN the_DT IFN-alpha/beta_NP family_NN ._SENT As_RB has_VBZ been_VBN reported_VBN for_IN previously_RB known_VBN IFNs_NP ,_, limitin_NN inhibits_VBZ not_RB only_JJ B_NP lymphopoiesis_NN but_CC also_RB proliferation_NN of_IN a_DT variety_NN of_IN lympho-hematopoietic_JJ cell_NN lines_NNS ._SENT Limitin_NP enhances_VBZ major_JJ histocompatibility_NN antigen_NN expression_NN on_IN antigen-presenting_NN cells_NNS ,_, as_RB well_RB as_IN the_DT killer_NN activity_NN of_IN cytotoxic_JJ T_NN lymphocytes_NNS ._SENT However_RB ,_, limitin_NN is_VBZ unique_JJ among_IN IFNs_NP because_IN it_PP has_VBZ no_DT influence_NN on_IN the_DT proliferation_NN of_IN normal_JJ myeloid_JJ and_CC erythroid_JJ progenitors_NNS ._SENT Although_IN limitin_NN transduces_VBZ signals_NNS via_IN the_DT IFN-alpha/beta_NP receptor_NN ,_, its_PP$ signals_NNS could_MD be_VB different_JJ from_IN those_DT of_IN IFN-alpha_NP and_CC IFN-beta_NP ._SENT In_IN this_DT study_NN ,_, we_PP show_VBP that_IN limitin_NN has_VBZ antivial_JJ activity_NN ,_, a_DT major_JJ biological_JJ function_NN of_IN IFNs_NP ,_, and_CC we_PP clarify_VBP the_DT difference_NN between_IN signals_NNS induced_VBN by_IN limitin_NP and_CC IFN-alpha_NP ._SENT Cells_NNS and_CC mice_NNS ._SENT |_SYM A_DT murine_JJ myeloid_JJ leukemia_NN cell_NN line_NN (_( WEHI3_NP )_) ,_, a_DT murine_JJ fibroblast_NN cell_NN line_NN (_( L929_NP )_) ,_, and_CC a_DT murine_JJ brain_NN tumor_NN cell_NN line_NN (_( DBT_NP )_) were_VBD maintained_VBN in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP 's_POS medium_NN (_( Nikken_NP ,_, Kyoto_NP ,_, Japan_NP )_) supplemented_VBD with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN (_( Flow_NP ,_, Aurora_NP ,_, Ohio_NP )_) ._SENT Cultured_JJ fibroblasts_NNS were_VBD generated_VBN from_IN murine_JJ lungs_NNS and_CC maintained_VBN in_IN Dulbecco_NP 's_POS modified_JJ Eagle_NP 's_POS medium_NN supplemented_VBD with_IN 10_CD %_NN fetal_JJ calf_NN serum_NN ._SENT IFN_NP regulatory_JJ factor_NN 1_CD (IRF-1)-deficient_NN mice_NNS were_VBD kindly_RB provided_VBN by_IN T._NP Taniguchi_NP (_( Tokyo_NP University_NP ,_, Tokyo_NP ,_, Japan_NP )_) ._SENT C57BL/6_NP mice_NNS were_VBD purchased_VBN from_IN Japan_NP Clea_NP (_( Tokyo_NP ,_, Japan_NP )_) and_CC used_VBN as_IN control_NN wild-type_NN mice_NNS for_IN IRF-1-deficient_JJ mice_NNS ._SENT BALB/c_NN mice_NNS were_VBD purchased_VBN from_IN Nippon_NP SLC_NP (_( Shizuoka_NP ,_, Japan_NP )_) ._SENT All_DT mice_NNS were_VBD maintained_VBN under_IN specific-pathogen-free_JJ conditions_NNS at_IN the_DT Institute_NP for_IN Experimental_NP Animals_NPS ,_, Osaka_NP University_NP ._SENT The_DT mice_NNS were_VBD similar6_JJ to_TO 10_CD weeks_NNS of_IN age_NN at_IN the_DT time_NN of_IN use_NN ._SENT Viruses_NNS and_CC cytokines_NNS ._SENT |_SYM Encephalomyocarditis_NP virus_NN (_( EMCV_NP )_) and_CC L929_NP cells_NNS were_VBD kindly_RB provided_VBN by_IN M._NP Kohase_NP (_( National_NP Institute_NP of_IN Infectious_NP Disease_NP ,_, Tokyo_NP ,_, Japan_NP )_) ._SENT EMCV_NP was_VBD propagated_VBN in_IN L929_NP cell_NN cultures_NNS ._SENT Human_JJ herpes_NN simplex_JJ virus_NN type_NN 1_CD (_( HSV-1_NP )_) was_VBD isolated_VBN from_IN the_DT vesicle_NN of_IN a_DT patient_NN and_CC propagated_VBN in_IN L929_NP cell_NN cultures_NNS ._SENT Mouse_NP hepatitis_NP virus_NN type_NN 2_CD (_( MHV-2_NP )_) and_CC DBT_NP cells_NNS were_VBD kindly_RB provided_VBN by_IN F._NP Taguchi_NP (_( National_NP Institute_NP of_IN Neuroscience_NP ,_, Tokyo_NP ,_, Japan_NP )_) ._SENT MHV_NP was_VBD propagated_VBN in_IN DBT_NP cell_NN cultures_NNS ._SENT EMCV_NP and_CC HSV_NP were_VBD titrated_VBN by_IN the_DT cytopathic_JJ effect_NN (_( CPE_NP )_) dye_NN uptake_NN method_NN ,_, and_CC MHV_NP was_VBD titrated_VBN by_IN plaque_NN assay_NN ._SENT Recombinant_JJ murine_NN IFN-alpha_NP was_VBD purchased_VBN from_IN GIBCO_NP BRL_NP (_( Grand_NP Island_NP ,_, N.Y._NP )_) ._SENT The_DT production_NN and_CC purification_NN of_IN recombinant_JJ limitin_NN and_CC anti-limitin_JJ polyclonal_JJ antibody_NN were_VBD described_VBN in_IN a_DT previous_JJ article_NN ._SENT The_DT fusion_NN proteins_NNS limitin-immunoglobulin_NN (_( Ig_NP )_) and_CC CD44-Ig_NP were_VBD prepared_VBN as_IN described_VBN previously_RB ._SENT Gel_NN filtration_NN chromatography_NN ._SENT |_SYM Analysis_NN of_IN purified_VBN recombinant_JJ limitin_NN was_VBD performed_VBN by_IN gel_NN filtration_NN chromatography_NN using_VBG a_DT Superdex_NP 75_CD PC_NN 3.2/30_CD column_NN (_( Amersham_NP Biosciences_NP ,_, Piscataway_NP ,_, N.J._NP )_) ._SENT A_DT mobile_JJ phase_NN consisted_VBN of_IN 20_CD mM_NP Tris_NP HCl_NP ,_, pH_NN 8.0_CD ,_, and_CC 150_CD mM_NP sodium_NN chloride_NN ._SENT Eluted_VBN protein_NN was_VBD detected_VBN by_IN UV_NP light_NN at_IN 280_CD nm_NN ._SENT An_DT LMW_JJ calibration_NN kit_NN (_( Amersham_NP Biosciences_NP )_) was_VBD used_VBN as_IN a_DT standard_JJ protein_NN marker_NN ._SENT [_SYM 3H]thymidine_JJ incorporation_NN assay_NN ._SENT |_SYM WEHI3_NP cells_NNS were_VBD incubated_VBN in_IN flat-bottom_NN 96-well_NN microplates_NNS (_( Corning_NP Costar_NP ,_, Tokyo_NP ,_, Japan_NP )_) for_IN 48_CD h._NN The_DT cells_NNS were_VBD pulsed_VBN with_IN 0.5_CD muCi_NNS of_IN [_SYM 3H]thymidine_JJ (_( Amersham_NP ,_, Tokyo_NP ,_, Japan)/well_NP for_IN the_DT last_JJ 4_CD h_NN of_IN culture_NN and_CC then_RB harvested_VBN onto_IN glass_NN filters_NNS (_( Wallac_NP ,_, Turku_NP ,_, Finland_NP )_) with_IN a_DT semiautomatic_JJ cell_NN harvester_NN (_( Pharmacia_NP )_) ,_, and_CC incorporated_JJ radioactivity_NN was_VBD measured_VBN with_IN a_DT liquid_JJ scintillation_NN counter_NN ._SENT CPE_NP dye_NN uptake_NN method_NN ._SENT |_SYM Antiviral_JJ activity_NN was_VBD measured_VBN by_IN the_DT CPE_NP dye_NN uptake_NN method_NN with_IN minor_JJ modifications_NNS ._SENT Briefly_RB ,_, confluent_JJ monolayers_NNS of_IN L929_NP cells_NNS were_VBD exposed_VBN to_TO serial_JJ dilutions_NNS of_IN limitin_NP or_CC IFN-alpha_NP overnight_RB ,_, challenged_VBN with_IN either_DT EMCV_NP or_CC HSV_NP until_IN 75_CD to_TO 95_CD %_NN CPE_NN was_VBD evident_JJ ,_, and_CC stained_VBD with_IN naphthol_NN black_JJ solution_NN (_( 0.1_CD %_NN naphthol_NN blue-black_NN ,_, 0.1_CD %_NN acetic_JJ bicarbonate_NN ,_, 9_CD %_NN acetic_JJ acid_NN )_) ._SENT The_DT bound_JJ dye_NN in_IN the_DT wells_NNS of_IN the_DT microtiter_NN plates_NNS was_VBD eluted_VBN with_IN 100_CD mM_NP NaOH_NP ,_, and_CC the_DT optical_JJ density_NN at_IN 650_CD nm_NN (_( OD650_NP )_) was_VBD measured_VBN colorimetrically_RB using_VBG a_DT spectrophotometer_NN (_( Emax_NP precision_NN microplate_NN reader_NN ;_: Molecular_NP Devices_NPS )_) ._SENT Plaque_NN assay_NN ._SENT |_SYM DBT_NP cell_NN monolayer_NN cultures_NNS on_IN six-well_NN dishes_NNS were_VBD washed_VBN with_IN phosphate-buffered_JJ saline_NN (_( PBS_NP )_) and_CC inoculated_VBN with_IN MHV_NP for_IN 1_CD h._NN The_DT cultures_NNS were_VBD overlaid_VBN with_IN minimal_JJ essential_JJ medium_NN containing_VBG 1_CD %_NN Bacto_NP Agar_NP (_( Difco_NP ,_, Detroit_NP ,_, Mich._NP )_) and_CC 10_CD %_NN tryptose_JJ phosphate_NN broth_NN ._SENT After_IN 48_CD h_NN of_IN incubation_NN ,_, each_DT well_NN was_VBD stained_VBN by_IN a_DT second_JJ overlay_NN containing_VBG 1:10,000_CD neutral_JJ red_NN for_IN 12_CD h_NN ,_, and_CC then_RB the_DT plaques_NNS were_VBD counted_VBN ._SENT Northern_JJ blot_NN analysis_NN ._SENT |_SYM Total_NP RNAs_NP were_VBD isolated_VBN using_VBG a_DT TRIZOL_NP reagent_NN (_( Invitrogen_NP ,_, Carlsbad_NP ,_, Calif._NP )_) ._SENT The_DT RNAs_NP (_( 15_CD mug/lane_NN )_) were_VBD electrophoresed_VBN through_IN a_DT formaldehyde-agarose_JJ gel_NN and_CC transferred_VBN onto_IN a_DT nylon_NN membrane_NN (_( Amersham_NP ,_, Arlington_NP Heights_NP ,_, Ill._NP )_) ._SENT The_DT cDNA_NN fragments_NNS were_VBD labeled_VBN with_IN [_SYM 32P]dCTP_JJ using_VBG a_DT randomly_RB primed_VBN DNA-labeling_NP kit_NN (_( Boehringer_NP Mannheim_NP ,_, Indianapolis_NP ,_, Ind._NP )_) and_CC hybridized_VBD to_TO the_DT membrane_NN ._SENT The_DT blots_NNS were_VBD then_RB washed_VBN and_CC autoradiographed_VBN ._SENT The_DT cDNA_NN fragment_NN of_IN Mx1_NP was_VBD kindly_RB provided_VBN by_IN O._NP Haller_NP (_( Freiburg_NP University_NP ,_, Freiburg_NP ,_, Germany_NP )_) ,_, and_CC that_IN of_IN IRF-1_NP was_VBD a_DT kind_NN gift_NN of_IN Y._NP Kanakura_NP (_( Osaka_NP University_NP ,_, Osaka_NP ,_, Japan_NP )_) ._SENT The_DT cDNA_NN fragments_VBZ of_IN PKR_NP and_CC 2',5'-OAS_NP were_VBD amplified_VBN by_IN PCR_NP with_IN the_DT following_VBG primers_NNS :_: sense_VBP (_( 5'-TTAGGTGGATTTGGTCAA-3_NP '_POS )_) (_( 895_CD to_TO 912_CD )_) and_CC antisense_NN (_( 5'-TCGGTCCTTGGGTTTCTCTG-3_NP '_POS )_) (_( 1600_CD to_TO 1617_CD )_) for_IN PKR_NP and_CC sense_NN (_( 5'-GTCTCCAAGGTGGTGAAGGG-3_NP '_POS )_) (_( 201_CD to_TO 220_CD )_) and_CC antisense_NN (_( 5'-TACTCAAGTTGTGTCGGGTC-3_NP '_POS )_) (_( 781_CD to_TO 800_CD )_) for_IN 2',5'-OAS_NNS ._SENT 2',5'-OAS_JJ activity_NN ._SENT |_SYM Measurement_NN of_IN 2',5'-OAS_JJ activity_NN was_VBD performed_VBN using_VBG a_DT 2',5'-oligoadenyl-5'-triphosphate_JJ (_( 2-5A_JJ )_) radioimmunoassay_NN kit_NN (_( Eiken_NP Chemical_NP Co._NP ,_, Tokyo_NP ,_, Japan_NP )_) according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS and_CC with_IN some_DT modifications_NNS described_VBD elsewhere_RB ._SENT Briefly_RB ,_, L929_NP cells_NNS (_( 105_CD )_) were_VBD seeded_VBN in_IN 24-well_JJ plates_NNS and_CC stimulated_VBN with_IN limitin_NN for_IN the_DT appropriate_JJ time_NN ._SENT The_DT cells_NNS were_VBD then_RB suspended_VBN in_IN 1_CD ml_NN of_IN lysis_NN buffer_NN consisting_VBG of_IN 10_CD mM_NP HEPES_NP (_( pH_NN 7.5_CD )_) ,_, 50_CD mM_NP KCl_NP ,_, 3_CD mM_NP Mg(CHOO)2_NP ,_, 0.3_CD mM_NP EDTA_NP ,_, 1_CD mM_NNS 2-mercaptoethanol_JJ ,_, 20_CD %_NN glycerol_NN ,_, and_CC 0.5_CD %_NN NP-40_NN and_CC centrifuged_VBN at_IN 10,000_CD x_NN g_NN for_IN 5_CD min_NN at_IN 4C_JJ ._SENT Then_RB ,_, 50_CD mul_NN of_IN supernatant_JJ medium_NN and_CC cell_NN lysates_NNS was_VBD mixed_VBN with_IN 50_CD mul_NN of_IN poly(rI)_JJ poly(rC)_JJ agarose_NN beads_NNS and_CC then_RB incubated_VBN for_IN 10_CD min_NN at_IN room_NN temperature_NN ._SENT After_IN centrifugation_NN at_IN 400_CD x_NN g_NN for_IN 5_CD min_NN ,_, the_DT pellets_NNS were_VBD resuspended_VBN with_IN 500_CD mul_NN of_IN ATP_NP solution_NN and_CC incubated_VBN at_IN 37C_JJ for_IN 1_CD h._NN To_TO the_DT mixture_NN was_VBD added_VBN 100_CD mul_NN of_IN 125I-labeled_JJ 2-5A_JJ solution_NN to_TO quantify_VB the_DT 2-5A_NN produced_VBN by_IN enzymatic_JJ reaction_NN of_IN 2',5'-OAS_NP and_CC ATP_NP ._SENT The_DT mixture_NN was_VBD incubated_VBN at_IN 37C_JJ for_IN 1_CD h_NN and_CC centrifuged_VBN at_IN 800_CD x_NN g_NN for_IN 30_CD min_NN ._SENT After_IN the_DT beads_NNS were_VBD washed_VBN ,_, their_PP$ radioactivity_NN was_VBD measured_VBN with_IN a_DT well-type_JJ gamma_NN counter_NN (_( WALLAC_NP WIZARD_NP 1470_CD )_) ._SENT The_DT amounts_NNS of_IN 2-5A_JJ synthesized_VBN by_IN 2',5'-OAS_NNS were_VBD calculated_VBN from_IN the_DT standard_JJ curve_NN ._SENT Infection_NN ._SENT |_SYM Mice_NN were_VBD infected_VBN intraperitoneally_RB with_IN an_DT appropriate_JJ dose_NN of_IN virus_NN and_CC then_RB treated_VBN intraperitoneally_RB with_IN limitin_NP or_CC PBS_NP ._SENT The_DT procedures_NNS were_VBD in_IN compliance_NN with_IN the_DT guidelines_NNS set_VBN by_IN the_DT institute_NN for_IN care_NN and_CC use_NN of_IN laboratory_NN animals_NNS ._SENT GPT_NP enzyme_NN activity_NN ._SENT |_SYM The_DT concentrations_NNS of_IN glutamate_NN pyruvate_NNS transaminase_NN (_( GPT_NP )_) in_IN the_DT sera_NN of_IN MHV-infected_JJ mice_NNS were_VBD measured_VBN using_VBG a_DT Rikitech_NP GPT_NP IFCC_NP assay_NN kit_NN (_( Roche_NP Diagnostics_NP ,_, Tokyo_NP ,_, Japan_NP )_) ._SENT Histopathological_JJ analysis_NN ._SENT |_SYM Histopathological_JJ examinations_NNS were_VBD carried_VBN out_IN using_VBG paraffin-embedded_JJ sections_NNS of_IN livers_NNS from_IN mice_NNS infected_VBN with_IN MHV_NP ._SENT The_DT sections_NNS were_VBD deparaffinized_VBN and_CC stained_VBN with_IN hematoxylin-eosin_NN ._SENT Luciferase_NN assay_NN ._SENT |_SYM Luciferase_NP assays_NNS were_VBD performed_VBN using_VBG the_DT Dual-Luciferase_NP Reporter_NP System_NP (_( Promega_NP ,_, Madison_NP ,_, Wis._NP )_) ,_, in_IN which_WDT transfection_NN efficiency_NN was_VBD monitored_VBN by_IN cotransfected_JJ pRL-SV40_NN (_( Promega_NP )_) ,_, an_DT expression_NN vector_NN of_IN Renilla_NP luciferase_NN ._SENT The_DT cultured_JJ cells_NNS were_VBD transfected_VBN with_IN 500_CD ng_NNS of_IN pCIS-ISRE_NN (_( Stratagene_NP ,_, La_NP Jolla_NP ,_, Calif._NP )_) ,_, together_RB with_IN 50_CD ng_NNS of_IN pRL-SV40_NN ,_, by_IN the_DT Lipofectamine_NP transfection_NN method_NN (_( Invitrogen_NP )_) ._SENT The_DT transfected_JJ cells_NNS were_VBD lysed_VBN in_IN buffer_NN supplied_VBN by_IN the_DT manufacturer_NN ,_, followed_VBN by_IN measurement_NN of_IN the_DT firefly_NN and_CC Renilla_NP luciferase_NN activities_NNS on_IN a_DT luminometer_NN (_( LB96P_NP ;_: Berthold_NP Japan_NP ,_, Tokyo_NP ,_, Japan_NP )_) ._SENT The_DT relative_JJ firefly_NN luciferase_NN activities_NNS were_VBD calculated_VBN by_IN normalizing_VBG transfection_NN efficiencies_NNS according_VBG to_TO the_DT Renilla_NP luciferase_NN activities_NNS ._SENT Recombinant_JJ limitin_NN protein_NN ._SENT |_SYM We_PP made_VBD recombinant_JJ limitin_NN protein_NN from_IN a_DT stably_RB limitin-producing_JJ Chinese_JJ hamster_NN ovarian_JJ cancer_NN cell_NN line_NN as_IN previously_RB described_VBN ._SENT When_WRB the_DT purity_NN of_IN recombinant_JJ protein_NN was_VBD evaluated_VBN by_IN gel_NN filtration_NN chromatography_NN ,_, only_RB one_CD large_JJ peak_NN whose_WP$ molecular_JJ mass_NN was_VBD similar20_JJ kDa_NN was_VBD seen_VBN ._SENT The_DT activity_NN of_IN recombinant_JJ limitin_NN protein_NN was_VBD also_RB confirmed_VBN by_IN the_DT previously_RB clarified_VBN limitin_NN function_NN ._SENT Limitin_NP suppressed_VBD the_DT proliferation_NN of_IN WEHI3_NP cells_NNS in_IN a_DT dose-dependent_JJ manner_NN ,_, and_CC the_DT activity_NN of_IN limitin_NN was_VBD stronger_JJR than_IN that_DT of_IN the_DT fusion_NN protein_NN limitin-Ig_NN at_IN the_DT same_JJ concentration_NN ._SENT Therefore_RB ,_, our_PP$ recombinant_JJ protein_NN ,_, whose_WP$ purity_NN is_VBZ >98_JJ %_NN ,_, has_VBZ higher_JJR specific_JJ activity_NN than_IN limitin-Ig_NN ._SENT In_IN this_DT study_NN ,_, we_PP used_VBD this_DT lot_NN of_IN recombinant_JJ limitin_NN protein_NN to_TO analyze_VB the_DT antiviral_JJ activity_NN of_IN limitin_NN ._SENT Limitin_NP has_VBZ antiviral_JJ activity_NN in_IN vitro_NN ._SENT |_SYM When_WRB L929_NP cells_NNS were_VBD infected_VBN with_IN EMCV_NP ,_, CPE_NP was_VBD detected_VBN within_IN 24_CD h._NN As_IN shown_VBN in_IN Fig._NN ,_, CPE_NN after_IN EMCV_NP infection_NN was_VBD inhibited_VBN by_IN limitin_NN in_IN a_DT dose-dependent_JJ manner_NN ._SENT The_DT antiviral_JJ activity_NN of_IN limitin_NN was_VBD evident_JJ at_IN 15_CD pg/ml_NN and_CC maximal_JJ at_IN 100_CD pg/ml_NN ,_, and_CC 30_CD pg_NN of_IN limitin/ml_NN provided_VBD 50_CD %_NN inhibition_NN of_IN CPE_NP ,_, which_WDT was_VBD similar_JJ to_TO that_DT of_IN the_DT control_NN IFN-alpha_NP ._SENT The_DT inhibition_NN of_IN CPE_NN by_IN limitin_NN was_VBD completely_RB cancelled_VBN by_IN the_DT addition_NN of_IN anti-limitin_JJ polyclonal_JJ antibody_NN ._SENT In_IN contrast_NN ,_, the_DT anti-limitin_NN antibody_NN could_MD not_RB cancel_VB the_DT inhibition_NN of_IN CPE_NP by_IN IFN-alpha_NP ._SENT These_DT facts_NNS indicate_VBP that_IN the_DT anti-limitin_NN antibody_NN is_VBZ specific_JJ to_TO limitin_NN and_CC that_DT limitin_NN truly_RB induces_VBZ an_DT antiviral_JJ state_NN in_IN L929_NP cells_NNS ._SENT Although_IN CPE_NP of_IN L929_NP cells_NNS was_VBD observed_VBN 72_CD h_NN after_IN HSV_NP infection_NN ,_, limitin_NN exhibited_VBD dose_NN dependency_NN for_IN antiviral_JJ activity_NN similar_JJ to_TO that_DT of_IN IFN-alpha_NP ,_, and_CC the_DT dose_NN of_IN both_DT limitin_NN and_CC IFN-alpha_NP that_WDT provided_VBD 50_CD %_NN inhibition_NN of_IN CPE_NP against_IN HSV_NP was_VBD also_RB similar30_JJ pg/ml_NN ._SENT Limitin_NP ,_, as_RB well_RB as_IN IFN-alpha_NP ,_, also_RB inhibited_VBD plaque_NN formation_NN by_IN MHV_NP in_IN DBT_NP cells_NNS ._SENT Therefore_RB ,_, limitin_NN displays_NNS antiviral_JJ activity_NN in_IN vitro_NN against_IN three_CD kinds_NNS of_IN viruses_NNS :_: EMCV_NP ,_, HSV_NP ,_, and_CC MHV_NP ._SENT The_DT concentration_NN (_( 30_CD pg/ml_NN )_) of_IN limitin_NP and_CC IFN-alpha_NP that_WDT provided_VBD a_DT 50_CD %_NN inhibition_NN of_IN CPE_NP in_IN L929_NP cells_NNS (_( with_IN EMCV_NP as_IN the_DT challenge_NN virus_NN )_) was_VBD defined_VBN as_IN 1_CD experimental_JJ unit_NN (EU)/ml_NN in_IN the_DT subsequent_JJ experiments_NNS ._SENT In_IN vivo_JJ antiviral_JJ activity_NN of_IN limitin_NN ._SENT |_SYM To_TO investigate_VB the_DT antiviral_JJ activity_NN of_IN limitin_NN in_IN vivo_JJ ,_, limitin_NN was_VBD injected_VBN intraperitoneally_RB every_DT day_NN into_IN MHV-infected_JJ mice_NNS ._SENT The_DT mice_NNS injected_VBN with_IN PBS_NP ,_, but_CC not_RB those_DT injected_VBN with_IN limitin_NN ,_, started_VBD to_TO die_VB within_IN 5_CD days_NNS after_IN MHV_NP infection_NN (_( data_NNS not_RB shown_VBN )_) ._SENT We_PP evaluated_VBD the_DT GPT_NP concentrations_NNS in_IN serum_NN with_IN the_DT GPT_NP IFCC_NP assay_NN and_CC analyzed_VBD hepatitis_NN histologically_RB 3_CD days_NNS after_IN MHV_NP infection_NN ._SENT In_IN mice_NNS injected_VBN with_IN PBS_NP ,_, the_DT GPT_NP concentrations_NNS in_IN serum_NN were_VBD markedly_RB elevated_VBN ,_, and_CC their_PP$ liver_NN sections_NNS revealed_VBD massive_JJ infiltration_NN of_IN lymphocytes_NNS ,_, massive_JJ necrosis_NN of_IN hepatocytes_NNS ,_, and_CC intrahepatic_JJ hemorrhage_NN ._SENT In_IN mice_NNS injected_VBN with_IN limitin_NN ,_, neither_DT elevation_NN of_IN the_DT GPT_NP concentration_NN in_IN serum_NN nor_CC the_DT hepatitis_NN effects_NNS in_IN liver_NN sections_NNS were_VBD observed_VBN ._SENT When_WRB BALB/c_NP mice_NNS were_VBD infected_VBN with_IN HSV_NP ,_, they_PP started_VBD to_TO die_VB within_IN 7_CD days_NNS after_IN infection_NN ,_, and_CC similar50_JJ %_NN of_IN the_DT mice_NNS in_IN the_DT PBS-treated_JJ group_NN died_VBD during_IN our_PP$ observation_NN period_NN ._SENT In_IN the_DT limitin-treated_JJ group_NN ,_, all_DT mice_NNS survived_VBN throughout_IN the_DT period_NN ._SENT HSV_NP was_VBD then_RB inoculated_VBN into_IN athymic_JJ nude_JJ mice_NNS ._SENT Although_IN limitin_NN could_MD not_RB rescue_VB the_DT HSV-infected_JJ mice_NNS ,_, administration_NN of_IN limitin_NN apparently_RB prolonged_VBD their_PP$ survival_NN compared_VBN with_IN that_DT with_IN PBS_NP injection_NN ._SENT Therefore_RB ,_, limitin_NN injection_NN produces_VBZ antiviral_JJ status_NN against_IN MHV_NP ,_, as_RB well_RB as_IN HSV_NP ,_, in_IN mice_NNS ._SENT Induction_NN of_IN antivirus-related_JJ genes_NNS ._SENT |_SYM PKR_NP activates_VBZ eIF-2alpha_NN ,_, which_WDT inhibits_VBZ mRNA_NN translation_NN ._SENT 2',5'-OAS_NP activates_VBZ RNase_NP L_NP ,_, leading_VBG to_TO RNA_NP degradation_NN ,_, by_IN producing_VBG 2-5A_JJ ._SENT Mx1_NP is_VBZ a_DT GTPase_NN that_WDT affects_VBZ the_DT intracellular_JJ transport_NN of_IN viral_JJ particles_NNS ._SENT Whole-cell_NN lysates_NNS of_IN L929_NP cells_NNS stimulated_VBN with_IN limitin_NN contained_VBD approximately_RB twice_RB the_DT 2',5'-OAS_JJ enzyme_NN activity_NN of_IN controls_NNS (_( 0.24_CD +-_NN 0.05_CD pmol/dl/cell/h_NN with_IN PBS_NP versus_CC 0.55_CD +-_NN 0.04_CD pmol/dl/cell/h_NN with_IN limitin_NN at_IN 4_CD h_NN )_) ._SENT In_IN addition_NN ,_, the_DT enhanced_JJ enzyme_NN activity_NN was_VBD also_RB detected_VBN in_IN the_DT supernatants_NNS of_IN limitin-stimulated_JJ L929_NP cells_NNS (_( data_NNS not_RB shown_VBN )_) ._SENT Message_NN of_IN 2',5'-OAS_NNS was_VBD also_RB induced_VBN after_IN limitin_NN stimulation_NN ,_, and_CC it_PP was_VBD enhanced_VBN till_IN 16_CD h_NN after_IN the_DT stimulation_NN ._SENT Although_IN PKR_NP mRNA_NP consists_VBZ of_IN three_CD transcripts_NNS of_IN 6.0_CD ,_, 4.0_CD ,_, and_CC 2.5_CD kbp_NN ,_, only_RB 6-kbp_JJ mRNA_NN was_VBD induced_VBN by_IN limitin_NP and_CC IFN-alpha_NP in_IN L929_NP cells_NNS ._SENT Only_RB weak_JJ message_NN of_IN Mx_NP protein_NN was_VBD induced_VBN within_IN 8_CD h_NN after_IN limitin_NN stimulation_NN (_( data_NNS not_RB shown_VBN )_) ,_, because_IN L929_NP cells_NNS were_VBD derived_VBN from_IN C3H/He_NP mice_NNS ,_, which_WDT belong_VBP to_TO the_DT phenotypically_RB Mx-_JJ strain_NN ._SENT When_WRB L929_NP cells_NNS were_VBD stimulated_VBN with_IN limitin_NN ,_, messages_NNS of_IN 2',5'-OAS_NP and_CC PKR_NP were_VBD induced_VBN as_RB strongly_RB as_IN with_IN IFN-alpha_NP ._SENT Therefore_RB ,_, limitin_NN induces_VBZ 2',5'-OAS_NNS ,_, PKR_NP ,_, and_CC Mx_NP proteins_NNS ,_, which_WDT mainly_RB mediate_VBP an_DT antiviral_JJ state_NN via_IN IFNs_NP ._SENT Different_JJ requirements_NNS for_IN IRF-1_NP by_IN limitin_NP and_CC IFN-alpha_NP for_IN induction_NN of_IN antiviral_JJ activity_NN ._SENT |_SYM Activation_NN of_IN signal_NN transducer_NN and_CC activator_NN of_IN transcription_NN 1_CD (_( STAT1_NP )_) is_VBZ essential_JJ for_IN the_DT antiviral_JJ activity_NN of_IN IFNs_NP ._SENT A_DT heterotrimer_NN composed_VBN of_IN STAT1_NP ,_, STAT2_NP ,_, and_CC IRF-9_NP binds_VBZ to_TO the_DT interferon-stimulated_JJ response_NN element_NN (_( ISRE_NP )_) that_WDT exists_VBZ in_IN the_DT promoters_NNS of_IN 2',5'-OAS_NP ,_, PKR_NP ,_, and_CC Mx1_JJ genes_NNS ._SENT The_DT STAT1_NP homodimer_NN is_VBZ another_DT mediator_NN ,_, and_CC it_PP transduces_VBZ IRF-1_NP ,_, which_WDT recognizes_VBZ consensus_NN promoter_NN sequences_NNS in_IN part_NN overlapping_VBG the_DT ISRE_NN ._SENT Our_PP$ Northern_JJ blotting_VBG revealed_VBD that_IN limitin_JJ enhanced_JJ IRF-1_JJ gene_NN expression_NN within_IN 2_CD h_NN in_IN L929_NP cells_NNS (_( data_NNS not_RB shown_VBN )_) ,_, and_CC the_DT message_NN was_VBD induced_VBN more_RBR strongly_RB than_IN by_IN IFN-alpha_NP 4_CD h_NN after_IN stimulation_NN ._SENT To_TO further_RBR examine_VB the_DT contribution_NN of_IN the_DT IRF-1-dependent_JJ pathway_NN ,_, we_PP performed_VBD a_DT CPE_NP dye_NN uptake_NN assay_NN using_VBG IRF-1-deficient_JJ fibroblasts_NNS ._SENT As_IN shown_VBN in_IN Fig._NN ,_, the_DT antiviral_JJ activity_NN of_IN limitin_NN was_VBD impaired_VBN more_RBR severely_RB than_IN that_DT of_IN IFN-alpha_NP in_IN IRF-1-deficient_JJ fibroblasts_NNS (_( the_DT doses_NNS that_WDT provided_VBD 50_CD %_NN inhibition_NN of_IN CPE_NP were_VBD 3_CD EU/ml_NN with_IN limitin_NN versus_IN 3_CD EU/ml_NN with_IN IFN-alpha_NP in_IN wild-type_NN fibroblasts_NNS and_CC 7_CD to_TO 8_CD EU/ml_NN with_IN limitin_NN versus_IN 3_CD to_TO 4_CD EU/ml_NN with_IN IFN-alpha_NP in_IN IRF-1-deficient_JJ fibroblasts_NNS )_) ._SENT The_DT reduced_VBN antiviral_JJ activity_NN of_IN limitin_NN was_VBD observed_VBN in_IN fibroblasts_NNS established_VBN from_IN six_CD independent_JJ IRF-1-deficient_JJ mice_NNS ._SENT The_DT relatively_RB higher_JJR requirement_NN for_IN IRF-1_NP for_IN the_DT limitin-induced_JJ antiviral_JJ state_NN was_VBD also_RB confirmed_VBN by_IN ISRE-luciferase_JJ reporter_NN assays_NNS ._SENT IRF-1-deficient_JJ fibroblasts_NNS stimulated_VBN by_IN limitin_NN produced_VBD less_JJR luciferase_NN protein_NN from_IN the_DT ISRE_NP sequence_NN than_IN those_DT stimulated_VBN by_IN IFN-alpha_NP ,_, while_IN similar_JJ luciferase_NN production_NN was_VBD observed_VBN in_IN wild-type_NN fibroblasts_NNS ._SENT Therefore_RB ,_, IRF-1_NP is_VBZ more_RBR critical_JJ for_IN the_DT limitin-mediated_JJ antiviral_JJ state_NN than_IN for_IN the_DT IFN-alpha-mediated_JJ antiviral_JJ state_NN ._SENT A_DT novel_JJ IFN-like_JJ cytokine_NN ,_, limitin_NN ,_, has_VBZ in_IN vitro_NN and_CC in_IN vivo_JJ antiviral_JJ activity_NN in_IN part_NN via_IN induction_NN of_IN PKR_NP ,_, Mx_NP protein_NN ,_, and_CC 2',5'-OAS_NP ,_, which_WDT inhibit_VBP viral_JJ replication_NN and_CC degrade_VB viral_JJ components_NNS ._SENT Although_IN limitin_NN has_VBZ antiviral_JJ activity_NN as_IN strong_JJ as_RB that_IN of_IN IFN-alpha_NP ,_, IRF-1_JJ dependencies_NNS for_IN induction_NN of_IN an_DT antiviral_JJ state_NN were_VBD different_JJ in_IN limitin_NP and_CC IFN-alpha_NP ._SENT These_DT findings_NNS support_VBP the_DT notion_NN that_IN a_DT human_JJ homolog_NN of_IN limitin_NN may_MD be_VB applicable_JJ as_IN a_DT new_JJ therapeutic_JJ drug_NN ._SENT Mice_NNS lacking_VBG the_DT IFN-alpha/beta_NP receptor_NN are_VBP abnormally_RB sensitive_JJ to_TO certain_JJ kinds_NNS of_IN viruses_NNS ,_, suggesting_VBG a_DT critical_JJ role_NN for_IN IFN-alpha/beta_NP cytokines_NNS in_IN this_DT type_NN of_IN immune_JJ defense_NN ._SENT As_RB described_VBN here_RB ,_, limitin_NN has_VBZ antiviral_JJ activity_NN like_IN those_DT of_IN IFN-alpha_NP and_CC IFN-beta_NP ._SENT Limitin_NP inhibited_VBD not_RB only_JJ CPE_NN in_IN EMCV-_NP or_CC HSV-infected_NP L929_NP cells_NNS ,_, but_CC also_RB plaque_NN formation_NN in_IN MHV-infected_JJ DBT_NN cells_NNS ,_, indicating_VBG that_IN limitin_NN displayed_VBD antiviral_JJ activity_NN against_IN at_IN least_JJS three_CD types_NNS of_IN viruses_NNS :_: EMCV_NP (_( RNA_NP nonenveloped_NN )_) ,_, HSV-1_NP (_( DNA_NP enveloped_VBD )_) ,_, and_CC MHV-2_NP (_( RNA_NP enveloped_VBD )_) ._SENT We_PP also_RB showed_VBD that_DT administration_NN of_IN limitin_NN to_TO mice_NNS suppressed_VBN MHV-induced_NP hepatitis_NP and_CC HSV-induced_NP death_NN ._SENT These_DT facts_NNS suggest_VBP that_IN limitin_NN may_MD be_VB applicable_JJ clinically_RB as_IN an_DT antiviral_JJ drug_NN ._SENT Interestingly_RB ,_, the_DT antiviral_JJ effects_NNS of_IN limitin_NN were_VBD higher_JJR in_IN BALB/c_NP mice_NNS than_IN in_IN athymic_JJ nude_JJ mice_NNS ._SENT Thus_RB ,_, in_IN addition_NN to_TO direct_JJ effects_NNS of_IN antiviral_JJ activity_NN ,_, limitin_NN seems_VBZ to_TO have_VB indirect_JJ antiviral_JJ activity_NN ,_, such_JJ as_IN induction_NN of_IN IFNs_NP ,_, enhancement_NN of_IN apoptosis_NN of_IN virus-infected_JJ cells_NNS ,_, activation_NN of_IN natural_JJ killer_NN cells_NNS ,_, and_CC induction_NN of_IN nitric_JJ oxide_NN ,_, which_WDT eliminate_VBP invading_VBG viruses_NNS in_IN vivo_RB ._SENT Viruses_NNS are_VBP intracellular_JJ pathogens_NNS ,_, and_CC IFNs_NP are_VBP thought_VBN to_TO constitute_VB the_DT first_JJ line_NN of_IN defense_NN in_IN host_NN resistance_NN to_TO virus_NN infections_NNS before_IN immune_JJ mechanisms_NNS come_VBN into_IN play_NN ._SENT It_PP is_VBZ noteworthy_JJ that_IN the_DT antiviral_JJ effects_NNS of_IN IFNs_NNS and_CC limitin_NN in_IN vivo_RB may_MD be_VB different_JJ ._SENT IFNs_NNS seem_VBP to_TO inhibit_VB the_DT expansion_NN and/or_CC extension_NN of_IN virus_NN infections_NNS ,_, because_IN IFN-alpha_NP and_CC IFN-beta_NP are_VBP induced_VBN by_IN double-stranded_JJ nucleic_JJ acids_NNS that_WDT are_VBP frequently_RB produced_VBN as_IN a_DT result_NN of_IN viral_JJ replication_NN ._SENT Previous_JJ data_NNS from_IN immunohistological_JJ staining_VBG showing_NN that_IN limitin_NN is_VBZ produced_VBN constitutively_RB in_IN healthy_JJ mice_NNS may_MD suggest_VB that_DT limitin_NN mainly_RB inhibits_VBZ invasion_NN of_IN the_DT body_NN by_IN viruses_NNS ._SENT This_DT possibility_NN may_MD also_RB be_VB supported_VBN by_IN the_DT fact_NN that_IN the_DT main_JJ limitin-producing_NN cells_NNS are_VBP T_NN lymphocytes_NNS and_CC bronchial_JJ epithelial_JJ cells_NNS ,_, a_DT major_JJ entrance_NN for_IN viruses_NNS into_IN the_DT body_NN ._SENT IFNs_NNS can_MD act_VB directly_RB at_IN various_JJ stages_NNS of_IN the_DT virus_NN infectious_JJ cycle_NN ,_, including_VBG penetration_NN ,_, transcription_NN ,_, translation_NN ,_, and_CC budding_VBG from_IN the_DT cell_NN surface_NN ._SENT Some_DT IFN-inducible_JJ proteins_NNS ,_, such_JJ as_IN PKR_NP and_CC 2',5'-OAS_NP ,_, inhibit_VBP translation_NN of_IN viral_JJ mRNA_NN ,_, and_CC 2',5'-OAS_NP also_RB leads_VBZ to_TO RNA_NP degradation_NN ._SENT Another_DT IFN-inducible_JJ protein_NN ,_, Mx_NP protein_NN ,_, inhibits_VBZ virus_NN replication_NN ._SENT PKR_NP ,_, Mx_NP protein_NN ,_, and_CC 2',5'-OAS_NNS may_MD participate_VB in_IN the_DT limitin-induced_JJ antiviral_JJ state_NN ,_, because_IN limitin_NN can_MD enhance_VB these_DT proteins_NNS in_IN fibroblasts_NNS ._SENT The_DT available_JJ information_NN suggests_VBZ that_IN there_EX are_VBP two_CD major_JJ pathways_NNS for_IN induction_NN of_IN gene_NN expression_NN of_IN PKR_NP ,_, Mx_NP protein_NN ,_, and_CC 2',5'-OAS_NNS ._SENT In_IN general_NN ,_, ligation_NN of_IN IFN-alpha_NP and_CC IFN-beta_NP to_TO the_DT IFN-alpha/beta_NP receptor_NN causes_VBZ phosphorylation_NN of_IN two_CD Janus_NP kinases_NNS ,_, Jak1_NP and_CC Tyk2_NP ,_, and_CC the_DT activated_VBN Jak1_NN then_RB phosphorylates_VBZ STAT1_NP and_CC STAT2_NP ._SENT The_DT phosphorylated_JJ Stat1-Stat2_NP complexes_NNS combine_VBP with_IN IRF-9_NP and_CC migrate_VB to_TO the_DT nucleus_NN ,_, where_WRB they_PP bind_VBP to_TO DNA_NP (_( the_DT ISRE_NP sequence_NN )_) and_CC initiate_VB the_DT transcription_NN of_IN PKR_NP ,_, Mx1_NP ,_, and_CC 2',5'-OAS_NNS ._SENT Another_DT important_JJ pathway_NN is_VBZ mediated_VBN by_IN the_DT Stat1-Stat1_NP homodimer_NN ,_, which_WDT binds_VBZ to_TO IFN-gamma-activated_JJ sequence_NN ,_, resulting_VBG in_IN transcription_NN of_IN IRF-1_NP ._SENT IRF-1_NP recognizes_VBZ consensus_NN promoter_NN sequences_NNS in_IN part_NN overlapping_VBG the_DT ISRE_NN ._SENT In_IN addition_NN ,_, at_IN least_JJS nine_CD IRF_NP members_NNS have_VBP been_VBN identified_VBN ,_, and_CC some_DT interact_VBP with_IN each_DT other_JJ ,_, resulting_VBG in_IN modification_NN of_IN their_PP$ transcriptional_JJ activities_NNS ._SENT Although_IN signals_NNS from_IN the_DT IFN-alpha/beta_NP receptor_NN are_VBP complex_JJ ,_, the_DT important_JJ roles_NNS of_IN Stat1_NP ,_, IRF-1_NP ,_, and_CC IRF-9_NP in_IN IFN-induced_NP antiviral_JJ activity_NN have_VBP been_VBN clarified_VBN by_IN experiments_NNS using_VBG knockout_JJ mice_NNS ._SENT Our_PP$ data_NNS clearly_RB indicate_VBP that_IN signals_NNS for_IN induction_NN of_IN an_DT antiviral_JJ state_NN are_VBP different_JJ for_IN limitin_NP and_CC IFN-alpha_NP ,_, while_IN limitin_NN has_VBZ antiviral_JJ activity_NN as_IN strong_JJ as_RB that_IN of_IN IFN-alpha_NP ._SENT Transcriptional_JJ activity_NN from_IN ISRE_NP sequence_NN ,_, as_RB well_RB as_IN the_DT antiviral_JJ activity_NN of_IN limitin_NN ,_, was_VBD impaired_VBN more_RBR severely_RB than_IN that_DT of_IN IFN-alpha_NP in_IN IRF-1-deficient_JJ fibroblasts_NNS ._SENT Thus_RB ,_, the_DT IRF-1-dependent_JJ signaling_VBG pathway_NN is_VBZ more_RBR critical_JJ for_IN the_DT limitin-mediated_JJ antiviral_JJ state_NN than_IN for_IN the_DT IFN-alpha-mediated_JJ antiviral_JJ state_NN ._SENT Although_IN direct_JJ proof_NN is_VBZ lacking_VBG ,_, the_DT phosphorylation_NN rates_NNS of_IN Stat1_NP and_CC Stat2_NP or_CC the_DT association_NN rates_NNS of_IN Stat1-Stat1_NP and_CC Stat1-Stat2-IRF9_NP might_MD be_VB different_JJ for_IN limitin_NP and_CC IFN-alpha_NP ._SENT Alternatively_RB ,_, limitin_NN might_MD induce_VB more_JJR or_CC fewer_JJR signals_NNS that_WDT modify_VBP the_DT activities_NNS of_IN the_DT IRF_NP family_NN than_IN IFN-alpha_NP ._SENT This_DT is_VBZ the_DT first_JJ report_NN showing_VBG that_IN signals_NNS are_VBP different_JJ for_IN limitin_NP and_CC IFN-alpha_NP ._SENT While_IN limitin_NN transduces_VBZ signals_NNS via_IN the_DT IFN-alpha/beta_NP receptor_NN ,_, there_EX are_VBP some_DT precedents_NNS for_IN the_DT unique_JJ signals_NNS of_IN limitin_NN ._SENT Differences_NNS between_IN IFN-alpha_NP and_CC IFN-beta_NP affinities_NNS for_IN the_DT IFN-alpha/beta_NP receptor_NN have_VBP been_VBN described_VBN ,_, as_RB well_RB as_IN between_IN subtypes_NNS of_IN IFN-alpha_NP ._SENT The_DT beta-R1_JJ gene_NN is_VBZ induced_VBN by_IN IFN-beta_NP but_CC not_RB by_IN IFN-alpha_NP ._SENT Association_NP of_IN a_DT 95-_CD to_TO 100-kDa_NP tyrosine-phosphorylated_JJ protein_NN with_IN the_DT IFN-alpha/beta_NP receptor_NN was_VBD found_VBN in_IN an_DT IFN-beta-_NP but_CC not_RB an_DT IFN-alpha-treated_JJ myeloma_NN cell_NN line_NN ._SENT On_IN the_DT other_JJ hand_NN ,_, recent_JJ advances_NNS in_IN the_DT structural_JJ and_CC functional_JJ analysis_NN of_IN IFN-alpha/beta_NP cytokines_NNS allow_VBP us_PP to_TO discuss_VB the_DT interactions_NNS between_IN IFNs_NP and_CC the_DT IFN-alpha/beta_NP receptor_NN ._SENT The_DT three-dimensional_JJ crystal_NN structures_NNS of_IN murine_JJ IFN-alpha_NP and_CC IFN-beta_NP revealed_VBD that_IN they_PP have_VBP a_DT globular_JJ structure_NN with_IN five_CD alpha-helices_NNS (_( A_DT to_TO E_NP )_) and_CC four_CD loops_NNS ._SENT Experiments_NNS using_VBG monoclonal_NN antibodies_NNS against_IN IFNs_NP and_CC site-directed_JJ mutagenesis_NN revealed_VBD the_DT functional_JJ importance_NN of_IN the_DT N-terminal_JJ half_NN of_IN the_DT loop_NN AB_NP and_CC the_DT loop_NN DE_NN ,_, together_RB with_IN the_DT nearest_JJS segments_NNS of_IN the_DT helices_NNS D_NP and_CC E._NP The_DT sequence_NN identity_NN between_IN limitin_NP and_CC IFNs_NP is_VBZ still_RB similar60_JJ %_NN ,_, even_RB in_IN the_DT functionally_RB important_JJ portions_NNS ._SENT The_DT diversity_NN of_IN signals_NNS among_IN IFN-alpha/beta_NP cytokines_NNS ,_, including_VBG limitin_NN ,_, might_MD be_VB explained_VBN by_IN differences_NNS in_IN their_PP$ interactions_NNS with_IN the_DT IFN-alpha/beta_NP receptor_NN or_CC by_IN differences_NNS in_IN their_PP$ sites_NNS that_DT bind_NN to_TO the_DT IFN-alpha/beta_NP receptor_NN ._SENT IFN-alpha_NP and_CC IFN-beta_NP are_VBP used_VBN for_IN the_DT treatment_NN of_IN patients_NNS with_IN AIDS-related_JJ Kaposi_NP 's_POS sarcoma_NN ,_, as_RB well_RB as_IN chronic_JJ hepatitis_NP B_NP and_CC C_NP ._SENT IFN-alpha-treated_JJ patients_NNS have_VBP a_DT significantly_RB higher_JJR rate_NN of_IN HBe_NP antigen_NN seroconversion_NN and_CC suppression_NN of_IN hepatitis_NP B_NP virus_NN DNA_NN ._SENT IFN-alpha_NP decreases_VBZ the_DT hepatitis_NP C_NP virus_NN load_NN and_CC reduces_VBZ the_DT risk_NN for_IN development_NN of_IN hepatocellular_JJ carcinoma_NN ._SENT In_IN spite_NN of_IN wide_JJ acceptance_NN of_IN IFNs_NNS as_IN therapeutic_JJ drugs_NNS ,_, they_PP produce_VBP some_DT adverse_JJ reactions_NNS ._SENT Some_DT patients_NNS chronically_RB treated_VBN with_IN IFNs_NP experience_NN weight_NN loss_NN ,_, bone_NN marrow_NN suppression_NN ,_, alopecia_NN ,_, thyroid_JJ dysfunction_NN ,_, and_CC depression_NN and_CC other_JJ psychiatric_JJ disorders_NNS ._SENT These_DT severe_JJ problems_NNS sometimes_RB require_VBP dose_NN reduction_NN or_CC discontinuation_NN of_IN treatment_NN ._SENT Another_DT clinical_JJ problem_NN is_VBZ that_IN several_JJ virus-derived_JJ proteins_NNS enable_VBP viruses_NNS themselves_PP to_TO evade_VB the_DT antiviral_JJ activities_NNS of_IN IFN-alpha_NP and_CC IFN-beta_NP ._SENT The_DT conventional_JJ IFN_NP monotherapy_NN is_VBZ effective_JJ in_IN only_RB a_DT small_JJ fraction_NN of_IN patients_NNS with_IN chronic_JJ hepatitis_NP C._NP Furthermore_NP ,_, the_DT hepatitis_NP C_NP virus_NN titer_NN often_RB rebounds_VBZ after_IN cessation_NN of_IN IFN_NP treatment_NN ._SENT To_TO increase_VB the_DT sustained_JJ response_NN rate_NN ,_, increasing_VBG IFN_NP dosage_NN ,_, prolonging_VBG the_DT duration_NN of_IN IFN_NP treatment_NN ,_, and/or_CC combination_NN therapy_NN with_IN other_JJ antiviral_JJ drugs_NNS ,_, such_JJ as_IN ribavirin_NN ,_, is_VBZ often_RB required_VBN ,_, although_IN adverse_JJ reactions_NNS to_TO IFNs_NNS also_RB increase_VB ._SENT Limitin_NP has_VBZ some_DT important_JJ and_CC unique_JJ features_NNS described_VBD here_RB and_CC elsewhere_RB ._SENT Limitin_NP has_VBZ fewer_JJR myelosuppressive_JJ properties_NNS than_IN IFN-alpha_NP ,_, indicating_VBG that_IN high-dose-_NN and_CC long-duration_NN therapy_NN with_IN limitin_NN may_MD be_VB done_VBN more_RBR safely_RB than_IN with_IN IFN-alpha_NP and_CC IFN-beta_NP ._SENT Limitin_NP used_VBD different_JJ signals_NNS for_IN induction_NN of_IN antiviral_JJ activity_NN than_IN IFN-alpha_NP and_CC IFN-beta_NP ,_, suggesting_VBG that_IN limitin_NN might_MD be_VB effective_JJ for_IN IFN-alpha-resistant_JJ patients_NNS ._SENT A_DT human_JJ homolog_NN of_IN limitin_NN or_CC an_DT engineered_JJ cytokine_NN with_IN useful_JJ features_NNS of_IN the_DT limitin_NN structure_NN could_MD be_VB superior_JJ to_TO IFN-alpha_NP and_CC IFN-beta_NP in_IN clinical_JJ utility_NN ._SENT Characterization_NN of_IN recombinant_JJ limitin_NN ._SENT Characterization_NN of_IN recombinant_JJ limitin_NN ._SENT (_( A_NP )_) Gel_NP filtration_NN profile_NN of_IN limitin_NN on_IN a_DT high-performance_JJ liquid_JJ chromatography_NN Superdex_NP 75_CD PC_NN 3.2/30_CD column_NN precalibrated_VBN with_IN the_DT standard_JJ protein_NN markers_NNS ._SENT Recombinant_JJ limitin_NN (_( 1.5_CD mug_NN )_) was_VBD applied_VBN ,_, and_CC the_DT flow_NN rate_NN was_VBD 75_CD mul/min_NN ._SENT The_DT arrows_NNS indicate_VBP the_DT elution_NN peaks_NNS of_IN the_DT marker_NN proteins_VBZ (_( albumin_NN ,_, 67.0_CD kDa_NN [_SYM 1_CD ]_SYM ;_: ovalbumin_NN ,_, 43.0_CD kDa_NN [_SYM 2_CD ]_SYM ;_: chymotrypsinogen_NN A_NP ,_, 25.0_CD kDa_NN [_SYM 3_CD ]_SYM ;_: and_CC RNase_NP A_NP ,_, 13.7_CD kDa_NN [_SYM 4_CD ]_SYM )_) ._SENT (_( B_NP )_) WEHI3_NP cells_NNS (_( 2.5_CD x_SYM 103_CD )_) were_VBD seeded_VBN in_IN each_DT well_RB and_CC stimulated_VBN with_IN the_DT indicated_JJ dose_NN of_IN recombinant_JJ limitin_NN (_( solid_JJ circles_NNS )_) ,_, limitin-Ig_NP (_( open_JJ circles_NNS )_) ,_, and_CC CD44-Ig_NP (_( open_JJ squares_NNS )_) for_IN 48_CD h._NN The_DT results_NNS represent_VBP the_DT means_NN +-_NN standard_JJ deviations_NNS of_IN triplicate_JJ cultures_NNS ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN three_CD independent_JJ experiments_NNS ._SENT Reduction_NN of_IN susceptibility_NN of_IN L929_NP cells_NNS to_TO EMCV_NP by_IN limitin_NP and_CC IFN-alpha_NP ._SENT Reduction_NN of_IN susceptibility_NN of_IN L929_NP cells_NNS to_TO EMCV_NP by_IN limitin_NP and_CC IFN-alpha_NP ._SENT (_( A_NP )_) L929_NP cell_NN monolayers_NNS on_IN 96-well_NN plates_NNS were_VBD pretreated_VBN with_IN the_DT indicated_JJ concentrations_NNS of_IN limitin_NN (_( solid_JJ circles_NNS )_) or_CC IFN-alpha_NP (_( open_JJ circles_NNS )_) overnight_RB and_CC challenged_VBN with_IN EMCV_NP (_( 5_CD x_SYM 102_CD PFU/well_NP )_) ._SENT After_IN 24_CD h_NN of_IN incubation_NN ,_, the_DT cells_NNS protected_VBN from_IN EMCV_NP virulence_NN were_VBD evaluated_VBN by_IN the_DT CPE_NP dye_NN uptake_NN assay_NN ._SENT The_DT percent_NN inhibition_NN of_IN CPE_NP was_VBD calculated_VBN as_IN 100_CD x_NN [_SYM OD650_NP (_( each_DT sample_NN )_) -_: OD650_NP (_( virus_NN control)/OD650_NN (_( cell_NN control_NN )_) -_: OD650_NP (_( virus_NN control_NN )_) ]_SYM ._SENT The_DT results_NNS represent_VBP the_DT means_NN +-_NN standard_JJ deviations_NNS (_( SD_NP )_) of_IN triplicate_JJ cultures_NNS ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN three_CD independent_JJ experiments_NNS ._SENT (_( B_NP )_) Limitin_NP (_( 1,000_CD pg/ml_NN )_) or_CC IFN-alpha_NP (_( 1,000_CD pg/ml_NN )_) was_VBD incubated_VBN with_IN the_DT indicated_JJ antibodies_NNS (_( 10_CD mug/ml_NN )_) for_IN 30_CD min_NN on_IN ice_NN ._SENT L929_NP cells_NNS were_VBD cultured_VBN in_IN the_DT presence_NN of_IN the_DT mixtures_NNS overnight_RB and_CC then_RB challenged_VBN with_IN EMCV_NP (_( 5_CD x_SYM 102_CD PFU/well_NP )_) ._SENT After_IN 24_CD h_NN of_IN incubation_NN ,_, the_DT cells_NNS protected_VBN from_IN EMCV_NP virulence_NN were_VBD evaluated_VBN by_IN the_DT CPE_NP dye_NN uptake_NN assay_NN ._SENT The_DT results_NNS represent_VBP the_DT means_NN +-_NN SD_NN of_IN triplicate_JJ cultures_NNS ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN three_CD independent_JJ experiments_NNS ._SENT Antiviral_JJ effects_NNS of_IN limitin_NP and_CC IFN-alpha_NP against_IN HSV_NP and_CC MHV_NP ._SENT Antiviral_JJ effects_NNS of_IN limitin_NP and_CC IFN-alpha_NP against_IN HSV_NP and_CC MHV_NP ._SENT (_( A_NP )_) L929_NP cell_NN monolayers_NNS on_IN 96-well_NN plates_NNS were_VBD pretreated_VBN with_IN the_DT indicated_JJ concentrations_NNS of_IN limitin_NN (_( solid_JJ circles_NNS )_) or_CC IFN-alpha_NP (_( open_JJ circles_NNS )_) overnight_RB and_CC challenged_VBN with_IN HSV_NP (_( 50_NP PFU/well_NP )_) ._SENT After_IN 72_CD h_NN of_IN incubation_NN ,_, the_DT cells_NNS protected_VBN from_IN EMCV_NP virulence_NN were_VBD evaluated_VBN by_IN the_DT CPE_NP dye_NN uptake_NN assay_NN ._SENT The_DT results_NNS represent_VBP the_DT means_NN +-_NN standard_JJ deviations_NNS (_( SD_NP )_) of_IN triplicate_JJ cultures_NNS ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN three_CD independent_JJ experiments_NNS ._SENT (_( B_NP )_) DBT_NN cells_NNS were_VBD seeded_VBN in_IN a_DT six-well_NN dish_NN ,_, and_CC then_RB the_DT subconfluent_JJ monolayer_NN was_VBD treated_VBN with_IN 30_CD EU_NP of_IN limitin/ml_NN or_CC 30_CD EU_NP of_IN IFN-alpha/ml_NP for_IN 24_CD h._NN The_DT pretreated_JJ DBT_NN cells_NNS were_VBD infected_VBN with_IN MHV_NP (_( 103_NP PFU/well_NP )_) for_IN 1_CD h_NN ,_, followed_VBN by_IN a_DT plaque_NN assay_NN ._SENT The_DT results_NNS represent_VBP the_DT means_NN +-_NN SD_NN of_IN triplicate_JJ cultures_NNS ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN three_CD independent_JJ experiments_NNS ._SENT Repression_NN of_IN MHV_NP infection_NN in_IN vivo_JJ by_IN limitin_NN ._SENT Repression_NN of_IN MHV_NP infection_NN in_IN vivo_JJ by_IN limitin_NN ._SENT (_( A_NP )_) Ten_NP BALB/c_NP mice_NNS were_VBD divided_VBN into_IN two_CD groups_NNS ._SENT One_CD group_NN was_VBD injected_VBN with_IN 3_CD x_SYM 104_CD EU_NP of_IN limitin/day_NN ._SENT The_DT other_JJ group_NN was_VBD treated_VBN with_IN PBS_NP as_IN controls_NNS ._SENT The_DT mice_NNS were_VBD treated_VBN intraperitoneally_RB with_IN PBS_NP or_CC limitin_NN on_IN days_NNS -1_CD ,_, 0_CD ,_, 1_CD ,_, and_CC 2_CD relative_NN to_TO MHV_NP exposure_NN (_( 103_CD PFU/mouse_NN )_) ._SENT After_IN 72_CD h_NN of_IN virus_NN inoculation_NN ,_, the_DT mice_NNS were_VBD anesthetized_VBN with_IN pentobarbital_NN and_CC bled_VBD to_TO measure_VB the_DT activity_NN of_IN GPT_NP in_IN serum_NN ._SENT Each_DT dot_NN represents_VBZ the_DT GPT_NP concentration_NN in_IN the_DT indicated_JJ mouse_NN ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN two_CD independent_JJ experiments_NNS ._SENT (_( B_NP )_) Two_NP mice_NNS from_IN each_DT group_NN were_VBD anatomized_VBN ,_, and_CC their_PP$ livers_NNS were_VBD investigated_VBN histologically_RB ._SENT Magnification_NN ,_, x100_NN ._SENT Prolongation_NN of_IN survival_NN of_IN HSV-challenged_JJ mice_NNS by_IN limitin_NN ._SENT Prolongation_NN of_IN survival_NN of_IN HSV-challenged_JJ mice_NNS by_IN limitin_NN ._SENT (_( A_NP )_) Twenty-four_NP BALB/c_NP mice_NNS were_VBD separated_VBN into_IN two_CD groups_NNS and_CC challenged_VBN with_IN HSV_NP (_( 5_CD x_SYM 104_CD PFU/mouse_NN )_) ._SENT The_DT mice_NNS were_VBD treated_VBN with_IN 3_CD x_SYM 104_CD EU_NP of_IN limitin_NN (_( solid_JJ circle_NN )_) or_CC PBS_NP (_( open_JJ circles)/mouse_NN on_IN days_NNS -1_CD ,_, 0_CD ,_, 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, and_CC 5_CD relative_NN to_TO HSV_NP exposure_NN ._SENT The_DT duration_NN of_IN observation_NN for_IN survival_NN was_VBD 14_CD days_NNS ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN two_CD independent_JJ experiments_NNS ._SENT (_( B_LS )_) Eighteen_JJ athymic_JJ nude_JJ mice_NNS were_VBD separated_VBN into_IN two_CD groups_NNS and_CC challenged_VBN with_IN HSV_NP (_( 104_CD PFU/mouse_NN )_) ._SENT The_DT mice_NNS were_VBD treated_VBN with_IN 3_CD x_SYM 104_CD EU_NP of_IN limitin_NN (_( solid_JJ circles_NNS )_) or_CC PBS_NP (_( open_JJ circles)/mouse_NN on_IN days_NNS -1_CD ,_, 0_CD ,_, 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ,_, and_CC 5_CD relative_NN to_TO HSV_NP exposure_NN ._SENT The_DT duration_NN of_IN observation_NN for_IN survival_NN was_VBD 14_CD days_NNS ._SENT Similar_JJ results_NNS were_VBD obtained_VBN in_IN two_CD independent_JJ experiments_NNS ._SENT Statistical_JJ analysis_NN was_VBD performed_VBN by_IN the_DT Kaplan-Meier_NP method_NN ,_, and_CC the_DT P_NN value_NN was_VBD calculated_VBN by_IN the_DT generalized_VBN Wilcoxon_NP test_NN ._SENT Induction_NN of_IN antiviral_JJ molecules_NNS by_IN limitin_NN ._SENT Induction_NN of_IN antiviral_JJ molecules_NNS by_IN limitin_NN ._SENT (_( A_NP )_) Whole-cell_NN lysates_NNS of_IN L929_NP cells_NNS stimulated_VBD w_NN 